| Online-Ressource |
Verfasst von: | Brands, Roman C. [VerfasserIn]  |
| Scheurer, Mario J. J. [VerfasserIn]  |
| Hartmann, Stefan [VerfasserIn]  |
| Seher, Axel [VerfasserIn]  |
| Freudlsperger, Christian [VerfasserIn]  |
| Moratin, Julius [VerfasserIn]  |
| Linz, Christian [VerfasserIn]  |
| Kübler, Alexander [VerfasserIn]  |
| Müller-Richter, Urs [VerfasserIn]  |
Titel: | Sensitization of head and neck squamous cell carcinoma to apoptosis by combinational SMAC mimetic and Fas ligand-Fc treatment in vitro |
Verf.angabe: | Roman C. Brands, Mario J.J. Scheurer, Stefan Hartmann, Axel Seher, Christian Freudlsperger, Julius Moratin, Christian Linz, Alexander C. Kübler, Urs D.A. Müller-Richter |
E-Jahr: | 2020 |
Jahr: | 2 June 2020 |
Umfang: | 9 S. |
Fussnoten: | Gesehen am 13.08.2020 |
Titel Quelle: | Enthalten in: Journal of cranio-maxillofacial surgery |
Ort Quelle: | Oxford [u.a.] : Elsevier, 1987 |
Jahr Quelle: | 2020 |
Band/Heft Quelle: | 48(2020), 7, Seite 685-693 |
ISSN Quelle: | 1878-4119 |
Abstract: | This study aimed to investigate the in vitro efficacy of three different SMAC mimetics for pro-apoptotic sensitization of HNSCC cells. We evaluated BV-6 in comparison to Birinapant and LCL161, for which pro-apoptotic sensitization effects have been demonstrated. Concentration-dependent response was measured for BV-6 in each cell line with an average IC50 value 8-fold lower than of aforementioned SMAC mimetics. Combination treatment of FasL (log2) and BV-6 (IC10) showed highly significant cell count reductions even in the lowest applied concentration in five cell lines (PCI-1: p = 0.0002, PCI-13: p = 0.0002, Detroit 562: p: p < 0.0001, FaDu: p < 0.0001, SCC-25: p = 0.0047). Synergistic effects (y < 1) were evident in eight out of 10 cell lines (PCI-1, PCI-9, PCI-13, PCI-68, Detroit 562, FaDu, SCC-25 and HaCaT). Annexin V assays revealed in nine cell lines very highly significant (p < 0.001) pro-apoptotic effects of BV-6. Western blots showed a heterogeneous IAP expression following SMAC mimetic treatment. Except for two cell lines, at least the cellular inhibitor of apoptosis protein 1 (cIAP1) was degraded in response to BV-6. For prospective targeted HNSCC therapy, this study identifies SMAC mimetics, particularly BV-6 as the compound with the highest pro-apoptotic potency, as promising antitumor agents. |
DOI: | doi:10.1016/j.jcms.2020.05.007 |
URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.1016/j.jcms.2020.05.007 |
| Volltext: http://www.sciencedirect.com/science/article/pii/S1010518220301281 |
| DOI: https://doi.org/10.1016/j.jcms.2020.05.007 |
Datenträger: | Online-Ressource |
Sprache: | eng |
Sach-SW: | Apoptosis |
| BV-6 |
| FasL |
| IAP |
| Sensitization |
| SMAC mimetics |
K10plus-PPN: | 1727016033 |
Verknüpfungen: | → Zeitschrift |
Sensitization of head and neck squamous cell carcinoma to apoptosis by combinational SMAC mimetic and Fas ligand-Fc treatment in vitro / Brands, Roman C. [VerfasserIn]; 2 June 2020 (Online-Ressource)